Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) saw strong trading volume on Tuesday . 143,190 shares changed hands during mid-day trading, an increase of 263% from the previous session’s volume of 39,453 shares.The stock last traded at $62.73 and had previously closed at $64.20.
Wall Street Analyst Weigh In
Separately, Zacks Research cut shares of Novozymes A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, August 25th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.
Read Our Latest Stock Report on NVZMY
Novozymes A/S Trading Down 2.2%
Novozymes A/S Cuts Dividend
The firm also recently declared a dividend, which will be paid on Thursday, September 11th. Investors of record on Wednesday, September 3rd will be given a dividend of $0.1856 per share. The ex-dividend date is Tuesday, September 2nd. This represents a yield of 88.0%. Novozymes A/S’s payout ratio is presently 48.10%.
About Novozymes A/S
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Featured Articles
- Five stocks we like better than Novozymes A/S
- Expert Stock Trading Psychology Tips
- Loop Industries Insiders Buy Stock, Signal Confidence in Outlook
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Joby Aviation’s Pullback: A Gift for Investors Who See the Future
- What Are Dividend Champions? How to Invest in the Champions
- Kohl’s Stock Rebound Faces a Showdown With Short Sellers
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.